Although this relative increase in risk in patients with cancer appears to be significantly lower than in the general population, the absolute increase in risk due to factor V Leiden may still be clinically significant in patients with cancer given their much higher baseline risk of VTE [2,15]. This evidence concerns the gene F5 and cancer.